9. Pascual JM. Animal models of the human mind: Is there anything like being autistic Neurosci Lett;505:59-60. 10. Pascual JM. Synaptic transporters are deceived if they think themselves free. Neurosci Lett;487:1-2. 11. Perez-Duenas B, Ormazabal A, Toma C, Torrico B, Cormand B, Serrano M, Sierra C, De Grandis E, Marfa MP, Garcia-Cazorla A, Campistol J, Pascual JM, Artuch R. Cerebral folate deficiency syndromes in childhood: clinical, analytical, and etiologic aspects. Arch Neurol;68:615-21. 12. Rogers ZR, Wang WC, Luo Z, Iyer RV, Shalaby-Rana E, Dertinger SD, Shulkin BL, Miller JH, Files B, Lane PA, Thompson BW, Miller ST, Ware RE, BABY HUG Investigators (including Dowling M). Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood;117:2614-7. 13. Scharner J, Brown CA, Bower M, Iannaccone ST, et al. Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Hum Mutat;32:152-67. 14. Sirsi D. Is intranasal midazolam better than rectal diazepam for home management of acute seizures Arch Neurol;68:120-1. 15. Tang W, Gilbreath H, Burns D, Iannaccone ST. Heat or exercise-induced rhabdomyolysis in ryanodine receptor channelopathy (33rd Annual Carrell-Krusen Neuromuscular Symposium, Texas Scottish Rite Hospital for Children, Dallas, Texas, February 17-18, 2011). J Clin Neuromuscular Disease 2011;12:13:173-95. 16. Wadman RI, Bosboom WM, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev:CD006282. 17. Wadman RI, Bosboom WM, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev:CD006281. 18. Waugh J, Plumb P, Rollins N, Dowling MM. Prolonged direct catheter thrombolysis of cerebral venous sinus thrombosis in children: a case series. J Child Neurol;27:337-45. 19. Zimmerman A, Clemens PR, Tesi-Rocha C, Connolly A, Iannaccone ST, et al. Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy. Muscle Nerve;44:170-3. Book Sections 1. Evans P. End-of-life-care for the neurologically impaired child. In: William, McGuire, Rizzo, eds. Practical Ethics in Clinical <strong>Neurology</strong>. Philadelphia, PA: American Academy of <strong>Neurology</strong>, LIppincott, Wilkins and Williams; 2011. 2. Evans P. Informed assent and refusal for children and adolescents. In: William, McGuire, Rizzo, eds. Practical Ethics in Clinical <strong>Neurology</strong>. Philadelphia, PA: American Academy of <strong>Neurology</strong>, LIppincott, Wilkins and Williams; 2011. 3. Evans P. Why, O God A Biblical theology of suffering and disability. In: Water L, ed. Practicing Inclusivity for Children with Special Needs. Wheaton, IL: Good News and Crossways Publishers; 2011. 4. Pascual JM. Disorders of muscle excitability. In: Brady ST, Siegel GJ, Albers RW, Price DL, eds. Basic Neurochemistry. 8th ed: Elsevier; 2011. 5. Pascual JM, DiMauro S. Disorders of the Krebs cycle and of pyruvate metabolism and transport. In: Rudolph CD, Rudolph AM, Lister G, First LR, Gershon AA, eds. Rudolph’s <strong>Pediatric</strong>s, 22nd edition. New York, NY: McGraw Hill; 2011. Grants Sponsored Clinical Trials Susan Arnold, M.D. Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox-Gastuat Syndrome Ovation Pharmaceuticals, OV-1004 Random, Double-Blind, Placebo-Controled, Parallel-Group Study with Open-Label Ext. Phase to Evaluate Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability and Pharmocokinetics when Administered as Adjunctive Therapy in Adolescents (12 to
Double Blind Placebo Controlled Dose-Escalation Study of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures Eisai Medical Research, Inc., E2007-G000-305 Susan Iannaccone, M.D. Open-Label Safety Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy PTC Therapeutics, Inc., PTC124-GD-016-DMD Phase 2b Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy PTC Therapeutics, Inc., PTC124-GD-007(e)-DMD 7